ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86778&wire=1 or contact Joseph E. Levi, Esq.

Exscientia plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86779&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Exscientia plc (EXAI) - June 25, 2024 Deadline to Join - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

Investors With Losses In Exscientia Plc Are Encouraged By The Schall Law Firm To Reach Out Please Be Aware Of The Deadline In This Case

NEW YORK , June 21, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Exscientia plc ("Exscientia" or the "Company") (NASDAQ: EXAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Exscientia investors who were adversely affected by alleged securities fraud between March 23, 2022 and February 12, 2024.

Exscientia plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86723&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc (EXAI)

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)

LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

Investors Who Have Incurred Losses In Exscientia Plc Are Encouraged By The Schall Law Firm To Establish Contact Please Be Mindful Of The Deadline In This Case

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c. (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline.

EXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI

NEW YORK , June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or "the Company") (NASDAQ:EXAI) and certain of its officers.

UPCOMING EXAI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Exscientia p.l.c. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86387&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Exscientia plc (EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86370&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Exscientia plc (EXAI) should contact Levi & Korsinsky about pending Class Action - EXAI

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

Investors With Losses In Exscientia Plc Are Urged By The Schall Law Firm To Make Contact Be Mindful Of The Matter Time Limit

The mean of analysts' price targets for Exscientia (EXAI) points to a 61.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43%

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86286&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Exscientia plc(EXAI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Exscientia p.l.c. (“Exscientia” or “the Company”) (NASDAQ: EXAI) and certain of its officers.

EXAI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Exscientia p.l.c. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES , June 18, 2024 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI).

EXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud Lawsuit

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI).

Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

LOS ANGELES , June 18, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

EXAI Investors Have Opportunity to Lead Exscienta plc Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=86098&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline - EXAI

LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

The Schall Law Firm Is Urging Investors Who Have Suffered Losses In Exscientia Plc To Reach Out. Please Be Aware Of The Time Limit In This Matter

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=85970&wire=1 or contact Joseph E. Levi, Esq.

Exscientia plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights – EXAI

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=85953&wire=1 or contact Joseph E. Levi, Esq.

June 25, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against EXAI

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

The Schall Law Firm Is Encouraging Investors Who Have Incurred Losses With Exscientia Plc To Make Contact. Please Note The Time Constraint In This Issue

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=85903&wire=1 or contact Joseph E. Levi, Esq.

News for ExScientia Ltd Stock (EXAI)